Drug intelligence / Profile preview

SER-444

Development stage: Preclinical
Lead developer: Serentrix
Modality: Small Molecules

Overview

SER-444 is a preclinical-stage small molecule transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist being developed by Serentrix. It is designed as a next-generation, thermally neutral TRPV1 antagonist to avoid the hyperthermia and altered heat pain perception side effects associated with first-generation TRPV1 inhibitors. Serentrix is developing SER-444 specifically for the treatment of vulvodynia.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on SER-444.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-444.